Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,494.46
    -1,693.02 (-3.37%)
     

  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Shire proposes $30 bln all-share tie-up with Baxalta

Reuters - UK Focus

LONDON, Aug 4 (Reuters) - London-listed pharmaceutical group Shire (Xetra: S7E.DE - news) said it was seeking to buy U.S. firm Baxalta (Berlin: 9BX.BE - news) in a $30 billion all-share deal to create a global specialist in medicines treating rare diseases with sales of $20 billion by 2020.

Shire went public with its proposal on Tuesday after Baxalta rejected the approach. Shire said it had offered to pay 0.1687 Shire ADR for each Baxalta share, implying a value of $45.23 per Baxalta share and a premium of 36 percent over Baxalta's stock price as on August 3.

Shares (Berlin: DI6.BE - news) in Shire were down 8 percent on the news. (Reporting by Paul Sandle; editing by Kate Holton)